Tag: osé
Oncology: OSE Immunotherapeutics receives 1.5 million euros from Bpifrance – 06/20/2023 at 18:07
(AOF) – OSE Immunotherapeutics announces today that it has received non-dilutive funding of 1.5 million euros from Bpifrance. The “R&D Innovation Loan” program aims to support the development of a…
OSE Immuno: receives funding of 1.5 ME from Bpifrance – 06/20/2023 at 18:09
(CercleFinance.com) – OSE Immunotherapeutics announces today that the Company has received non-dilutive financing of €1.5 million from Bpifrance – Direction Régionale de Nantes. This funding aims to accelerate the development…
OSE Immuno: receives funding of 1.5 ME from Bpifrance
(CercleFinance.com) – OSE Immunotherapeutics announces today that the Company has received non-dilutive financing of €1.5 million from Bpifrance – Direction Régionale de Nantes. This funding aims to accelerate the development…
OSE Immunotherapeutics presents the latest data on the BiCKI®IL-7, CLEC-1 and OSE-230 preclinical programs in Immuno-Oncology and Immuno-Inflammation At international conferences – 06/15/2023 at 07:30
Nantes, France – June 15, 2023, 7:30 a.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces that the latest scientific data has been selected for oral or poster presentations…
la Reine ose and a combinaison retro vaporeuse
Camilla Parker-Bowles a été aperçue avec a superbe combinaison bleu cobalt dimanche 11 june 2023. A look tendance que la pure porte très bien à 75 ans. Camilla Parker-Bowles a…
OSE Immuno: Eric Leire should join the Board of Directors
By Alexandra Saintpierre Published on 05/31/2023 at 6:16 p.m. (Boursier.com) — The Board of Directors ofOSE Immunotherapeutics,…
The Board of Directors of OSE Immunotherapeutics proposes the appointment of Éric Leire as a new independent director – 05/31/2023 at 18:00
To the General Shareholders’ Meeting of June 22, 2023 Nantes, May 31, 2023, 6 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Ticker: OSE) announces that the Board of Directors, on…
OSE Immuno: end of patient recruitment in the phase 2 clinical trial evaluating Tedopi in advanced pancreatic cancer
By Alexandra Saintpierre Published on 05/24/2023 at 6:19 p.m. (Boursier.com) — OSE Immunotherapeutics SA announces the end…
OSE Immunotherapeutics: end of recruitment for the Tedopi trial – 2023-05-24 at 18:13
(AOF) – OSE Immunotherapeutics SA announces the end of recruitment in the TEDOPaM phase 2 clinical trial, promoted and conducted by the Gercor group, which is evaluating Tedopi in advanced…
OSE Immunotherapeutics pursues clinical development in ulcerative colitis with full worldwide rights to Lusvertikimab – 05/12/2023 at 18:00
• Lusvertikimab (OSE-127), a ‘first-in-class’ product, is the most clinically advanced anti-IL-7R monoclonal antibody. • Ongoing phase 2 trial in ulcerative colitis (sponsor OSE Immunotherapeutics) after a positive futility analysis…
OSE Immunotherapeutics alone continues its clinical study on Lusvertikimab – 05/12/2023 at 18:11
(AOF) – OSE Immunotherapeutics announces that it is continuing its phase 2 clinical study of Lusvertikimab having obtained full worldwide rights to the product. OSE and Servier signed a two-step…
OSE Immuno: early access authorization for Tedopi in Spain
(CercleFinance.com) – OSE Immunotherapeutics announces today that AEMPS, the Spanish Medicines Agency, has made available a new early access program which will allow patients to have access to Tedopi® within…